Pipeline 4 Header Image

Engineering Novel Biologics

The Engineering Novel Biologics pipeline brings together three programs united by a shared focus on moving beyond binding alone and toward function, selectivity, mechanism, and therapeutic impact. Across the symposium and two conference tracks, attendees will explore how display technologies, multispecific architectures, and immune-engager strategies are collectively expanding what biologics can do and where they can work. The Display of Biologics Symposium centers on next-generation display platforms and function-first selection strategies for antibodies, non-antibody scaffolds, and emerging biologic modalities. The Multispecific Engineering and Design track examines computational and AI-driven design, smaller formats, immunomodulatory bispecifics, logic-gated, and payload-directed formats. The Emerging T Cell Engagers track takes a focused look at the design challenges shaping the next generation of TCEs, with particular emphasis on solid tumor activity, autoimmunity, and I&I, while also covering costimulation, cytokine modulation, synapse engineering, and emerging engagers beyond T cells.

January 18